Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial

作者: Rongyu Zang , Yanling Feng , Dongsheng Tu , Sheng Yin , Rong Jiang

DOI: 10.1016/S1470-2045(21)00006-1

关键词: Gynecologic oncologyMedicineInternal medicineInterim analysisCytoreduction Surgical ProceduresCarboplatinProgression-free survivalHazard ratioPopulationDocetaxel

摘要: Background The benefits of secondary cytoreduction for platinum-sensitive relapsed ovarian cancer are still widely debated. We aimed to assess the efficacy of secondary cytoreduction …

参考文章(25)
Ursula A. Matulonis, Amit M. Oza, Tony W. Ho, Jonathan A. Ledermann, Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials. Cancer. ,vol. 121, pp. 1737- 1746 ,(2015) , 10.1002/CNCR.29082
Thomas J. Herzog, Deborah K. Armstrong, Mark F. Brady, Robert L. Coleman, Mark H. Einstein, Bradley J. Monk, Robert S. Mannel, J. Tate Thigpen, Sharee A. Umpierre, Jeannine A. Villella, Ronald D. Alvarez, Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper Gynecologic Oncology. ,vol. 132, pp. 8- 17 ,(2014) , 10.1016/J.YGYNO.2013.11.008
Wen-Juan Tian, Dennis S. Chi, Jalid Sehouli, Claes G. Tropé, Rong Jiang, Ali Ayhan, Gennaro Cormio, Yan Xing, Georg-Peter Breitbach, Elena Ioana Braicu, Catherine A. Rabbitt, Halldis Oksefjell, Christina Fotopoulou, Hans-Gerd Meerpohl, Andreas du Bois, Jonathan S. Berek, Rong-Yu Zang, Philipp Harter, A Risk Model for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: An Evidence-Based Proposal for Patient Selection Annals of Surgical Oncology. ,vol. 19, pp. 597- 604 ,(2012) , 10.1245/S10434-011-1873-2
Gordon John Sampson Rustin, Ignace Vergote, Elizabeth Eisenhauer, Eric Pujade-Lauraine, Michael Quinn, Tate Thigpen, Andreas du Bois, Gunnar Kristensen, Anders Jakobsen, Satoru Sagae, Kathryn Greven, Mahesh Parmar, Michael Friedlander, Andres Cervantes, Jan Vermorken, Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). International Journal of Gynecological Cancer. ,vol. 21, pp. 419- 423 ,(2011) , 10.1097/IGC.0B013E3182070F17
Rong-Yu Zang, Zi-Ting Li, Jie Tang, Xi Cheng, Shu-Mo Cai, Zhi-Yi Zhang, Nelson N. Teng, Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer. ,vol. 100, pp. 1152- 1161 ,(2004) , 10.1002/CNCR.20106
R Y Zang, P Harter, D S Chi, J Sehouli, R Jiang, C G Tropé, A Ayhan, G Cormio, Y Xing, K M Wollschlaeger, E I Braicu, C A Rabbitt, H Oksefjell, W J Tian, C Fotopoulou, J Pfisterer, A du Bois, J S Berek, Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. British Journal of Cancer. ,vol. 105, pp. 890- 896 ,(2011) , 10.1038/BJC.2011.328
Dennis S Chi, Kristina McCaughty, John P Diaz, Jae Huh, Sarah Schwabenbauer, Amanda J Hummer, Ennapadam S Venkatraman, Carol Aghajanian, Yukio Sonoda, Nadeem R Abu‐Rustum, Richard R Barakat, None, Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. ,vol. 106, pp. 1933- 1939 ,(2006) , 10.1002/CNCR.21845
Philipp Harter, Andreas du Bois, Maik Hahmann, Annette Hasenburg, Alexander Burges, Sibylle Loibl, Martina Gropp, Jens Huober, Daniel Fink, Willibald Schröder, Karsten Muenstedt, Barbara Schmalfeldt, Guenter Emons, Jacobus Pfisterer, Kerstin Wollschlaeger, Hans-Gerd Meerpohl, Georg-Peter Breitbach, Berno Tanner, Jalid Sehouli, Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial Annals of Surgical Oncology. ,vol. 13, pp. 1702- 1710 ,(2006) , 10.1245/S10434-006-9058-0